How Is Ventas Positioned in 2018?

How Wall Street Analysts View Ventas

By Raina Brown
|
Feb 7, 2018 5:53 pm EST

Analyst ratings

Analyst ratings for Ventas (VTR) reflect its performance expectations for 2018. Analysts gave VTR a mean price target of $62.25, implying a ~11.2% rise from its current level of $55.97. It has a market capitalization of about $19.5 billion.

As of January 2018, two of 20 analysts covering the stock gave it “buy” or “strong buy” ratings, 14 gave it a “hold” rating, and the remaining four gave it a “sell” rating. The number of Ventas’s “strong buy” and “buy” ratings are consistent with December 2017.

Interested in HCN?
Don't miss the next report.

Receive e-mail alerts for new research on HCN

Success!
You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

VTR’s peer ratings

Among Ventas’s major alternative peers, Welltower (HCN) got a “buy” or “strong buy” rating from five of 22 analysts and a “hold” rating from 14 analysts. It got a “sell” rating from the remaining three analysts. The target price for HCN is $68.86, while the current price is $59.97.

Four of 20 analysts gave HCP (HCP) a “buy” or “strong buy” rating, 15 analysts gave it a “hold” rating, and the remaining one analyst gave it a “sell” rating. The target price for HCP is $27.78 compared to the current level of $24.08.

Ten of 12 analysts gave the Healthcare Trust of America (HTA) a “buy” or “strong buy” rating, while the remaining two gave it a “hold” rating. The target price for HTA is $33.63 compared to the current level of $27.61.

Investors looking for exposure to the healthcare real estate sector can invest in REIT ETFs. VTR forms 2.4% of the iShares Core U.S. REIT ETF (USRT).